Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window

Findings May Potentially Lead to New Approach to Stroke Treatment BOCA RATON, Fla., July 30 /PRNewswire-USNewswire/ -- When minimally invasive endovascular (through the vessel) therapy made its debut two decades ago, stroke care underwent a major shift as the "window of treatmen...

Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets

NEW YORK, July 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced approximately $2.1 million in total funding to 10 research teams working to validate therapeutic targets for Parkinson's disease. Target validation is an essentia...

Dry Mouth Linked to Prescription and Over the Counter Drugs

BALTIMORE, July 9 /PRNewswire-USNewswire/ -- Approximately ninety-one percent of dentists say patients complaining about dry mouth are taking multiple medications, according to a nationwide member survey conducted by the Academy of General Dentistry (AGD). Dry mouth, or xerostomia , is caused by...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and ...

MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease

NEW YORK, June 25 /PRNewswire-USNewswire/ -- As of mid-2009, The Michael J. Fox Foundation for Parkinson's Research has already funded over $1 million in high-risk, high-reward approaches to Parkinson's therapeutic development through its groundbreaking Rapid Response Innovation Awards . Projects...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

Improvements in Systolic Blood Pressure and Triglycerides Also Observed NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: ALKS ) today announced long-term, interim results from the ...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patie...

PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)

- Company Reports Significant Uptake of PlasmaBlade by U.S. Surgeons Since Product Launch - PALO ALTO, Calif., April 7 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that has developed a new tissue dissection system based on a proprietary technology, announced today several mil...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an 88 Percent Reduction in the Risk of Cardiac Death at Three Years ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Long-term data presen...

First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008

PARIS, March 24 /PRNewswire-FirstCall/ -- The AXA Research Fund closed out its first year of existence. During the year ended, the Fund granted more than Euro 13 million to various European research institutions. The purpose of the Fund is to promote the understanding and prevention of major ...

Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI

Angiomax Will Remain the NSTEMI Market Share Leader Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy...

The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership

DOYLESTOWN, Pa., Feb. 24 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY ) www.quigleyco.com , today announced that it has signed a license with assignment of ownership agreement for its patented formulation QR-340 developed by its wholly owned subsidiary, Quigley Pharma Inc. T...

Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests

FirstVue(TM) HBSAG Test Found to Have Higher Sensitivity and Specificity than Other Rapid HBSAG Tests and FirstVue(TM) '...and was the preferred test in all phases of this evaluation' CORAL SPRINGS, Fla., Oct. 13 /PRNewswire/ -- AT First Diagnostic LLC an emerging worldwide m...

Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period

Results of FLEXX Trial Presented at the Osteoarthritis Research Society International's 2008 World Congress PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Ferring Pharmaceuticals Inc. recently presented results from the FLEXX Trial of Osteoarthritis of the Knee, showing that EUFLEXXA(R) (1% sodium...

Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years

Results published in New England Journal of Medicine reaffirm well-established efficacy and long-term safety profile of SPIRIVA(R) HandiHaler(R) RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNewswire/ -- Results of the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropiu...

Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter

BRUSSELS, Belgium and GENEVA, Sept. 3 /PRNewswire/ -- Artelis SA and Selexis SA announced today a new milestone in CHO based monoclonal antibody production with the achievement of manufacturing yields of over 31 grams per liter. This record level was accomplished by applying two highly innovat...

Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile

LYON, France and SWIFTWATER, Pa., June 16 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization (WHO) over 3 years for the establishment of an H5N1 vaccine global...

New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes

SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- A head-to-head study announced today at the American Diabetes Association (ADA) meeting demonstrated that Levemir(R) (insulin detemir [rDNA origin] injection) can be used once-daily and had a comparable blood glucose response to insulin glargine ...

Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone

-- Clinical trial data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution presented at International ATS Conference -- NAPA, Calif., May 20 /PRNewswire/ -- Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that concomitant ...

Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol

SAN DIEGO, May 19 /PRNewswire/ -- DDW 2008 Annual Meeting -- Ethicon Endo-Surgery announced today that the results from its pivotal trial demonstrated physician/nurse teams using the SEDASYS(TM) System reduced the risk of over sedation with propofol in patients undergoing screening and diagnos...

Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year

- Cognitive Function Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting - SAN FRANCISCO and CHICAGO, April 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients treated with the investigatio...

Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis

Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and adv...

DermaGen AB Receives Over 1 Million Euros From a New Share Issue

LUND, Sweden, April 2 /PRNewswire/ -- DermaGen AB today announced a cash injection from Midroc New Technology AB who now joins existing owners, Karolinska Development and Ostersjostiftelsen. The capital will be used for the further development of DermaGen's first candidate drug. The majority w...

New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ

BRIDGEWATER, N.J., March 15 /PRNewswire-FirstCall/ -- Data presented at the annual meeting of the American Academy of Allergy Asthma & Immunology (AAAAI) suggests that the continuous use of intranasal corticosteroid Nasacort AQ (triamcinolone acetonide) Nasal Spray had no treatment effect on s...

AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine

Following FDA Approval, Company Announces $7,800 Wholesale Price for Lifesaving Drug LOS ANGELES, Jan. 21 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce...

AHF Seeks White House Clarification After Press Room Flap Over CDC's HIV Numbers

LOS ANGELES, Dec. 11 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) is seeking clarification from the White House regarding a press briefing late last week during which Deputy Press Secretary Dana Perino had a curt exchange with reporter Les Kingsolving over questions he tried to ...

Leukemia Drug Proves Safe and Effective Over the Long Term

WASHINGTON, Nov. 7, /PRNewswire-USNewswire/ -- The drug imatinib mesylate, more commonly known as Gleevec(R), proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML), according to a study prepublished online in Blood, the official journa...

ACC Concerned Over Reporting of Biomonitoring Results

ARLINGTON, Va., Oct. 23 /PRNewswire-USNewswire/ -- Last evening CNN and the Discovery Channel aired the documentary, Planet in Peril. The documentary touched on many environmental and resource issues around the globe. The American Chemistry Council (ACC) supports efforts like this that look ho...

Facet Solutions' AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing

LOGAN, Utah, Oct. 22 /PRNewswire/ -- Facet Solutions, Inc. announced today that testing conducted by Professor Vijay Goel, PhD., from the Department of Bioengineering at the University of Toledo, demonstrated that the Anatomic Facet Replacement System (AFRS(TM)) has shown biomechanical advanta...

Veto of California's Condoms in Prisons Bill: "Politics Over Public Health," Says AHF

AB 1334, (Swanson, D, Oakland), Sponsored by AIDS Healthcare Foundation (AHF), AIDS Project Los Angeles (APLA), and the Southern California HIV/AIDS Coalition (SCHAC) Could Have Helped Reduce Spread of HIV and Other STDs Among California Inmates Governor Instructs Department of Corrections to...

CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores

Annual Vaccination Program Begins October 1, 2007 WOONSOCKET, R.I., Sept. 19 /PRNewswire-FirstCall/ -- CVS/pharmacy today announced that it will help keep America healthy this winter by offering flu vaccinations in over 4,000 of its stores across the country. The flu shot clinics wi...

Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years

PHILADELPHIA, Pa., Sept. 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK ) today announced new results from a large study that demonstrate combination treatment with AVODART (dutasteride) and the alpha blocker tamsulosin provides significantly greater urinary symptom improvement for me...

New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia

CAIRNS, Australia, Aug. 31 /PRNewswire/ -- What and When Data from a six-month study of ramelteon will be presented in poster format at worldsleep07: The 5th World Congress of the World Federation of Sleep Research and Sleep Medicine Societies to be held in Cairns, Australia September 2-6, 2...

You May Have a Thyroid Problem and Not Know It - Particularly If You're Over 60, Says a New Harvard Medical School Report

BOSTON, Aug. 9 /PRNewswire-USNewswire/ -- Doctors often mistake the symptoms of thyroid disease for another disorder such as heart failure, high cholesterol, or even dementia, says a new edition of a report from Harvard Medical School. The symptoms of thyroid diseases are so wide-ranging, part...

GenoMed Prevents Sickle Cell Pain for Over a Year

ST. LOUIS--(BUSINESS WIRE)--Mar 12, 2007 - GenoMed (OTC Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today publication of a case report of a sickle cell patient whose pain has disappeared for over a year thanks to GenoMed's treatme...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by a Significant 43% in Acute Ischemic Stroke Patients Treated With Clexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ -- Sanofi-aventis announced the publication of the PREVAIL (Prevention of VTE after Acute Is...

Doctors Outraged Over Growth Hormone Controversy

Two anti-aging preventative medicine doctors say they are outraged over recent media coverage about their advocacy of prescribing human growth hormone to treat a hormone deficiency often associated with aging. DAYTONA BEACH, Fla., April 27, 2007 /PRNewswire/ -- The adult use of human growth hormon...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data have demonstrated that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE(R) (glatiramer acetate injection) following brief immunosuppression with mitoxantrone experienced a 90 percent reduction in magnetic resonanc...

Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

Phase III Clinical Data on Thalidomide in Multiple Myeloma Presented at the American Society of Clinical Oncology 43rd Annual Meeting CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation today reported the final results of a Phase III study demonstrating that the addition of Thali...

Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials

HOUSTON, June 04, 2007 /PRNewswire/ -- A nationally renowned cancer researcher affiliated with the US Oncology Research Network presented a novel study design concept called a Complete Phase Ib clinical trial as a method to accelerate new agent development. Studies utilizing this design are curren...